在生命最后阶段接受姑息性放疗的转移性癌症患者队列中对METSSS评分的验证与扩展
该研究纳入2010年1月至2019年12月在苏黎世大学医院放疗科于生命最后阶段接受姑息性放疗的全部患者,计算METSSS评分并分层,评估其对总生存的预测价值。共274例患者,METSSS评分将269例(98.1%)归为高危组、4例(1.5%)为中危组、1例(0.4%)为低危组,预测中位1年总生存率为10%。作者认为METSSS评分通过将患者归入最高风险类别正确预测了该终末期队列的生存,可作为分配症状性放疗的决策工具。
要点
- 274例终末期姑息放疗患者中,METSSS评分将98.1%(269例)归为高危组。
- 全组患者自放疗开始的中位实际总生存为40天,预测中位1年总生存率为10%。
- 作者认为METSSS评分正确预测了该终末期队列的生存,可作为症状性放疗决策工具。
核心结论
- 作者认为METSSS评分通过将终末期患者归入最高风险类别正确预测了其生存,可作为分配症状性放疗的决策工具。
研究设计与样本
- 研究纳入2010年1月至2019年12月在苏黎世大学医院放疗科于生命最后阶段接受姑息性放疗的全部患者。
主要发现
- 共274例患者接受生命最后阶段的姑息性放疗,其中女性34%(n=93)。
- 最常见原发肿瘤为肺癌(n=121,44%),55%(n=152)的患者按Charlson-Deyo合并症指数无合并症。
- 最常见放疗部位为脑和眼区域(42%,n=115)。
- 全组患者自放疗开始的中位实际总生存为40天。
- METSSS评分模型预测269例(98.1%)为高危组、4例(1.5%)为中危组、1例(0.4%)为低危组,预测中位1年总生存率为10%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION AND BACKGROUND: Choosing the right treatment for the right patient in a setting of metastatic cancer disease remains a challenge. To facilitate clinical decision-making, predictive tools have been developed to personalize treatment. Here, we aim to assess the use of the recently proposed "METSSS score" as a prognostic tool for overall survival of cancer patients after palliative radiotherapy in the last phase of life. METHODS: All patients treated with palliative radiotherapy at the end-of-life at the Department of Radiation Oncology of the University Hospital Zurich between January 2010 and December 2019 were included in this study. Data on demographics, diagnosis, treatment and comorbidities was extracted from the treatment planning and the electronical medical records system. To statistically assess the validity of the "METSSS score", the mortality risk score was calculated, followed by stratification of all patients to prognostic risk groups. The prediction of the 1-year overall survival estimates was subsequently calculated. RESULTS: Over the past decade, 274 patients have received palliative radiotherapy during the end-of-life period. One third of patients was female (34%, n = 93). The most frequent primary tumor was lung cancer (n = 121, 44%), and 55% of patients (n = 152) had no comorbidities according to the Charlson-Deyo comorbidity index. The most common radiotherapy site was the brain and eye region (42%, n = 115). The median actual overall survival of all patients was 40 days from the start of radiotherapy. The "METSSS score" survival model predicted that 269 patients (98.1%) belong into the high-risk, four patients (1.5%) into the medium-risk, and one patient (0.4%) into the low-risk group. The predicted median 1-year overall survival was 10%. DISCUSSION: The METSSS score correctly predicted the survival of our end-of-life patient cohort by assigning them into the highest risk category, and it can therefore serve as a decision-making tool when assigning patient to symptomatic radiotherapy.
引用
- Christ SM, Schettle M, Willmann J, et al. Validation and extension of the METSSS score in a metastatic cancer patient cohort after palliative radiotherapy within the last phase of life. Clin Transl Radiat Oncol. 2022. PMID: 35496816. doi:10.1016/j.ctro.2022.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。